One-day out-patient prescribing patterns at a national referral hospital in Kenya by Ambetsa, Margaret O et al.
Ambetsa et al, Afr. J. Pharmacol. Ther. 2017. 6(2): 96-101 
 
A KeSoBAP Publication ©2017. All rights reserved. 
96 
 
One-day out-patient prescribing patterns at a 
national referral hospital in Kenya  
Margaret O. Ambetsa a,b,*, Margaret N. Oluka a, Faith A. Okalebo a, Nicholas 
C. Mulwa a,b, Joseph Fadare c, Brian Godman d,e 
a Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, Kenya  
b Ministry of Health, Nairobi, Kenya  
c Department of Pharmacology, Ekiti State University, Ado-Ekiti, Nigeria  
d Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet/Karolinska 
University Hospital, Stockholm, Sweden  
e Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK 
_____________ 
 
* Corresponding author: Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of 
Nairobi, P.O. Box 19676-00202 , Nairobi, Kenya; Tel: +254-72-4725759; Email: ambetsamargie@gmail.com  
 
Background: Poor prescribing habits lead to ineffective and unsafe treatment for patients, exacerbating or 
prolonging of illness as well as causing distress and harm to them. Drug utilization studies can help identifying gaps in 
prescribing and feed the results back to prescribers to enhance future rational use of medicines.  
Objective: Evaluate outpatient prescribing practices and patterns in a leading national Hospital in Kenya. 
Methods: A sample of 60 prescriptions was selected by quasi-random sampling. Data was abstracted using a pre-
designed data collection form, entered into and analyzed using Excel software.  
Results: The average number of drugs prescribed per prescription was three with a polypharmacy rate (>4 drugs) of 
20%. Only two-thirds (65%) of the prescribed drugs were actually dispensed at the hospital pharmacy due to 
shortages, principally shortages of originators. Slightly more than half (52%) of the drugs were prescribed by generic 
name. Prescribing by brand names was highest among medical interns (61%). Almost all drugs prescribed (95%) 
were consistent with the hospital tender list.  
Conclusions: There is a need to increase the rate of prescribing of generics to save costs as well as reduce stock-out 
levels. This can be helped by instigating a comprehensive generics policy. There is also a need to strengthen and 
empower drugs and therapeutic committees (DTCs) to improve selection and availability of quality generics to win 
the confidence of prescribers. 
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1. Introduction 
Prescribing is an important step in the medicine use 
cycle. Inappropriate prescribing habits lead to 
ineffective treatment, greater toxicity and higher costs 
to the healthcare system and patients. Examples of 
inappropriate prescribing include poly pharmacy, 
prescribing of brand names rather than international 
non-proprietary name (INN) prescribing as well as the 
overuse of antibiotics (Cameron et al, 2012; Desalegn et 
al, 2013; Patterson et al, 2012; Markovic-Pekovic et al, 
2016; Godman et al, 2013a; Little et al, 2013). Poly 
pharmacy should be discouraged where possible as it 
increases the chance of adverse drug reactions and drug 
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interactions, the cost of drugs and promotes non-
adherence (Desalegn et al, 2013; Patterson et al, 2012; 
Markovic-Pekovic et al, 2016; Hines et al, 2011; 
Hamilton et al, 2009).  
In developing and transitional countries, it has been 
estimated that fewer than 40% of patients are currently 
treated in line with published guidelines (Holloway et 
al, 2011; Holloway et al, 2013). This is important given 
the current low spending on health care among African 
countries, especially in sub-Saharan Africa, and the high 
expenditure on pharmaceuticals that is a burden to 
these healthcare systems and patients (Kaseje et al, 
2006; Cameron et al, 2009). Some of the causes of 
inappropriate prescribing are inadequate knowledge 
about prescribing, pressure from patients, promotion 
by originator pharmaceutical companies including 
raising concerns with generics, and copying poor 
examples from fellow prescribers (Baumgärtel et al, 
2012; Bhartiy et al, 2008; Cessak et al, 2016; Civaner et 
al, 2012; Davis et al, 2013; Hassali et al, 2015; Labiris et 
al, 2015; MdRezal et al, 2015; Sabuncu et al, 2009; 
Spurling et al, 2010). 
Drug utilization studies such as prescription surveys 
can identify areas of concerns and provide feedback to 
prescribers to enhance the appropriate use of 
medicines. World Health Organization (WHO) 
prescribing indicators measure prescribing practices of 
health care providers and are useful tools to promote 
rational prescribing (WHO 1993). A recent review 
among developing and transitional countries suggested 
for instance that 45% to 54% of patient encounters still 
result in a prescription for antibiotics and only 65% of 
medicines are prescribed by generic name (Holloway, 
2013).  
This study sought to build on these studies by 
evaluating current prescribing practices and patterns in 
Kenya, initially at a national referral hospital. 
Subsequently, use these findings to develop future 
research strategies and initiatives to improve the 
appropriateness of future prescribing within our 
hospitals. 
2. Methods 
2.1 Study design 
A descriptive hospital based cross-sectional study was 
undertaken to describe a one-day prescribing patterns 
using the WHO prescribing and patient care indicators. 
The study was conducted on 13th June 2013.  
2.2 Study Site 
The study was carried out at the out-patient pharmacy 
of the Kenyatta National Hospital (KNH), which is the 
largest national teaching and referral hospital in Kenya. 
The hospital is located in Nairobi, Kenya’s capital city, 
and has a busy out-patient pharmacy that serves 
diverse patients from the Nairobi metropolis 
2.3 Sampling procedure 
A quasi-random sampling method was employed to 
obtain a sample size of one third (65) prescriptions out 
of the total population of 190 prescriptions received at 
the out-patient Pharmacy on 10th June 2013. One third 
was chosen to provide a reliable sample without being 
labour intensive. Prescriptions that were written before 
or after 10th June 2013 or those that did not originate 
from KNH were excluded. Out of the 65 prescriptions 
sampled, only 60 finally met the inclusion criteria and 
were therefore included in the study. We used the 
hospital drug tender list as a surrogate for the official 
drug policy documents such as the essential drugs list 
(EDL) or the hospital formulary since at the time of the 
study, the hospital formulary of KNH was still in the 
process of compilation.  
2.4 Data collection 
Data was abstracted from sampled prescriptions. A pre-
tested data abstraction form was used to collect 
relevant data pertaining to WHO prescribing and 
patient care indicators, patient demographic 
characteristics and prescriber characteristics. 
2.5 Outcomes 
Outcome measures included the number of medicines in 
a prescription, prescribing by generic name, poly 
pharmacy (four or more medicines per prescription) 
(Patterson et al, 2012), compliance with hospital 
medicine tender list/formulary when prescribing and 
percentage of medicines actually dispensed. The 
variables were patient sex, patient age, prescriber sex 
and prescriber cadre.  
2.6 Data analysis 
Data were analyzed using Excel software (MS Excel 
2007). All variables were subjected to descriptive data 
analysis. Continuous variables that were normally 
distributed were expressed as mean and standard 
deviation (SD). For continuous variables that were not 
normally distributed, the median and inter-quartile 
range (IQR) was reported. Categorical variables were 
reported as proportions. 
2.7 Ethical Considerations 
Permission to carry out the study was granted by the 
Kenyatta National Hospital. Data collected from 
prescriptions were coded to remove patient identifiers 
for confidentiality purposes.   
3. Results  
A total of 60 prescriptions were included in the study. 
The baseline characteristics of the study subjects are 
summarized in Table 1.  
Approximately two thirds (65%) of the study subjects 
were females. The median age for the subjects was 30 
(IQR: 15 – 43) years ranging from 5 to 75 years. Most of 
the prescribers were males (60%). Medical Interns 
generated half of the prescriptions.  
The average number of medicines prescribed per 
prescription was three. Slightly more than half (52%) of 
the drugs were prescribed by generic name, indicating 
that 48% of the medicines were prescribed by brand 
names.  
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Prescribing by brand names was more common with 
fixed-dose combination drugs (70%) compared to 
single formulations (30%). These results are 
summarized in Table 2. 
Table 1: Baseline characteristics of study subjects  
Baseline characteristic N=60 
Patient demographics:  
Sex:  
    Male n(%) 21 (35%) 
    Female n(%) 39 (65%) 
Age in years, Median (IQR) 30 (15 – 43) 
Prescriber characteristics:  
Sex:  
    Male n(%) 36 (60%) 
    Female n(%) 24 (40%) 
Cadre:  
Medical Interns n (%) 30 (50%) 
Medical Registrars n (%) 21 (35%) 
Medical Specialists/Consultants n (%)   9 (15%) 
 
Prescribing by brand name was highest among medical 
interns (61%), followed by medical 
specialists/consultants (52%), with medical registrars 
showing the least tendency to prescribe using brand 
names (34%).   
Only approximately two-thirds (65%) of the prescribed 
medicines could actually be dispensed in the out-patient 
pharmacy at the time implying a 35% stock-out level. 
Encouragingly, a high proportion of medicines 
prescribed (95%) were consistent with the hospital 
tender list.  
Prescription of four or more medicines per prescription 
(polypharmacy) was encountered in 20% of the 
prescriptions as shown in Table 3. 
4.0 Discussion 
This study described prescribing patterns using WHO 
prescribing and patient care indicators in an out-patient 
setting at Kenya’s largest referral hospital. 
Encouragingly, prescribing compliance to the hospital 
drug tender list was 95%, although lower than the WHO 
suggested threshold of 100%. However, this rate of 
compliance was higher than the 72.2% reported in a 
previous study in Kenya (Muyu et al, 2013).  
 
   Table 2: Prescribing and patient care indicators for study subjects  
Prescribing Indicators Number or % WHO threshold 
Average number of medicines  prescribed per prescription 3 <2 
% of medicines  prescribed by generic name 52% 100% 
% of medicines  actually dispensed per prescription 65 100% 
% of medicines  prescribed consistent with hospital tender 
list/Essential Drugs List or Formulary 
95% 100% 
Total number of prescriptions sampled 60  
Total number of medicines  prescribed 155  
 
    Table 3: The Distribution of the number of drugs per prescription among study subjects  
No. of drugs per prescription No. of prescriptions Percentage (%) 
1 9 15 
2 15 25 
3 24 40 
4 9 15 
>4 3 5 
Total 60 100 
 
The average number of medicines per prescription in 
this study was 3.0, which was higher than that observed 
in a recent Ethiopian study where there were 2.2 
medicines per prescription (Bilal et al, 2016). However, 
lower than the 4.0 medicines per prescription reported 
in another hospital based study in Kenya (Muyu et al, 
2013). Overall though, the degree of polypharmacy in 
this study was low at 20%. This could be attributed to 
the relatively youthful study population with a median 
age of 30 years (IQR 15-43), with a range of 5 to 75 
years, and mostly female (65%). Published studies have 
correlated polypharmacy with increasing age of 
patients and female gender (Holbeach et al, 2010), with 
co-morbidities and the resultant use of medicines 
increasing with age (Bushardt et al, 2008). Even though 
the polypharmacy observed in our study was not 
stratified by age and gender, it is possible to speculate 
that study subjects over 60 years were mainly female 
and prone to using multiple medications to manage 
their co-morbidities (Markovic-Pekovic et al, 2016). 
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Just over half the medicines in this study were 
prescribed by generic name (52%). This was much 
lower than the high rate of generic prescribing (97%) 
reported in the recent Ethiopian study (Bilal et al, 
2016); however, our findings were comparable to the 
low rates of generic prescribing (42% - 50%)  reported 
in tertiary care hospitals in Nigeria (Enwere et al, 2007, 
Tamuno et al, 2012). Encouragingly, our results were 
higher than the generic prescribing of 25.6% seen 
earlier in another public hospital in Kenya (Muyu et al, 
2013). The rate of generic prescribing observed in the 
Kenyan and Nigerian studies though were way below 
the suggested WHO threshold for generic prescribing 
(100%), and are reflective of the poor generic 
prescribing habits. This may be due to poor knowledge 
of prescribers regarding generic products including 
fears of therapeutic failure (Fadare et al, 2015).   
The high rate of prescribing branded products is a 
concern considering the low socioeconomic status of 
patients attending public hospitals.  The use of branded 
products has been associated with escalating costs of 
healthcare, with studies reporting that substantial 
savings can be realized by switching to generic 
prescribing in developing countries (Cameron et al, 
2012). The prescription of branded products in our 
study also contributed to the extent of drug stock-outs 
(35%), with stock out rates similar to the 45% reported 
in the study by Muyu et al (2013). This is against 
suggested WHO requirements that 100% of the 
medicines prescribed for patients in hospitals should be 
available at the health facility. Our findings point to a 
possible need to appreciably reduce direct promotional 
activities to clinicians by medical representatives and 
instead provide continuous medical education (CMEs) 
to motivate prescribers through peer modeling. This 
has been successful in for instance Stockholm County 
Council in Sweden, leading to high adherence rates in 
ambulatory care to a list of approximately 200 
medicines (Gustafsson et al, 2011; Bjorkhem-Bergman 
et al, 2013; Godman et al 2009). Also, there may be a 
need to strengthen and empower hospital drugs and 
therapeutic committees to improve selection and 
availability of quality generics to win the confidence of 
prescribers. Published studies have shown similar 
outcomes between generics of high quality and 
originators (brands) across a wide range of products 
and disease areas (Baumgartel et al, 2012; Kesselheim 
et al, 2008; Gagne et al, 2014; Paton et al, 2006; Veronin 
et al, 2011; Godman et al, 2015; Corrao et al, 2014). 
Failure by the hospital pharmacy to meet expectations 
in filling all prescriptions is likely to have negative 
health and economic consequences on patients such as 
worsening health conditions and the necessary 
purchase of more expensive medicines in the private 
sector.  
Our study did not explore the potential for a generic 
substitution policy across sectors. However, the recent 
study in tertiary institutions in Nigeria reported that 
most physicians (64%) would currently object to such a 
policy (Fadare et al, 2015). Another option is to start 
training physicians in medical schools to prescribe by 
the generic name only and follow-up with further 
education once qualified. This has worked well in the 
UK with INN prescribing rates of 98 – 99% across a 
range of molecules and classes (Godman et al, 2013b). 
In this study, medical interns had the highest tendency 
(61%) to prescribe medicines using brand names 
compared to medical registrars (34%).  Whilst there is a 
need to explore this further, we could speculate that it 
could be due to promotional activities of 
pharmaceutical companies targeting medical interns 
who are still inexperienced in medical practice.  Other 
studies have reported that promotional activities of 
pharmaceutical companies often have a strong influence 
on prescribing habits both in Africa (Fadare et al, 2015) 
and in other countries (Riaz et al, 2015). It is 
noteworthy that in Kenya, generic products exist as 
“branded generics” leading to a multiplicity of products 
containing the same active ingredient aggressively 
marketed by generic importers or local manufacturers 
Another interesting finding of this study was the 
observation that 70% of brand name prescribing was in 
fixed dose combinations (FDCs). This may be due to 
prescribers finding difficulty in writing out the lengthy 
generic names of the single constituents; alternatively 
pressure from pharmaceutical companies as the prices 
of FDCs may often be higher than the constituent parts 
(Kalaba et al, 2012). There is a steady rise in FDCs in 
Kenya especially for cardiovascular diseases, diabetes 
and pain management. So far no attempt has been made 
locally to rationalize the appropriateness of some of 
these combinations despite ongoing debate on their 
benefits regarding their effectiveness, compliance and 
typically a price premium versus titrating each 
component separately (Kalaba et al, 2012; Bangalore et 
al, 2007; Mancia et al 2009). This needs addressing in 
the future. 
Study limitations 
We are aware that this study covered only one day of 
prescribing practices while the WHO recommends that 
a drug indicator study should cover a longer period of 
time (WHO-1993). However, as a rapid assessment tool, 
the study has provided an impetus for further studies as 
well as provided a basis for discussions within the 
Ministry of Health in Kenya. 
5.0 Conclusion  
The degree of polypharmacy in this study was low at 
20%. This study also identified various shortcomings in 
prescribing practices in Kenya. Generic prescribing was 
low, with just over half the medicines prescribed by 
generic name. The high rate of prescribing branded 
products is a concern considering the low 
socioeconomic status of patients who attend public 
hospitals in Kenya.   
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